LIFS Stock UPDATES Life Stem Genetics Inc. (LIFS) 0.0900 08/20/2014
Post# of 273250
Sunshine Heart Appoints Brian Brown as Senior Vice President of Operations and Technology
GlobeNewswire - Mon Jun 16, 4:29AM CDT
Sunshine Heart, Inc. (Nasdaq:SSH) today announced the appointment of Brian Brown to the position of Senior Vice President of Operations and Technology. In this capacity, Mr. Brown will manage the Company's R & D program for its flagship C-Pulse(R) Heart Assist System, a medical device addressing Class III and ambulatory Class IV heart failure. Additionally, Mr. Brown will be responsible for operations inclusive of internal and contracted manufacturing.
Life Stem Genetics hires Dr Vino Padayachee as director and board chair
M2 - Fri Mar 21, 5:32AM CDT
Cell therapies company Life Stem Genetics (Other OTC:LIFS) revealed on Thursday that it has appointed Dr Vino Padayachee as director and chairman of its board of directors.
Life Stem Genetics appoints Dr. Vino Padayachee as Director and Chairman of the Board of Directors
PR Newswire - Thu Mar 20, 8:30AM CDT
Life Stem Genetics, Inc. (LIFS), an emerging innovator in the advancement of Adult Stem Cell therapies, today announced the appointment of Dr. Vino Padayachee, a well-known family physician/anesthetist, as Director and Chairman of the Board of Directors of the company. Dr. Padayachee has been actively involved in the Saskatchewan Medical Association as a member of the Representative Assembly, the Board of Directors, and the executive. He served as Chief of Staff of St. Joseph's Hospital in Estevan, Saskatchewan, from 1998 to 2009, as Chief of Staff of South East Health District from 1999 to 2004, and as Chief of Staff of Sun Country Health Region from 2004 to 2008. He was the first Clinical Chair for the Health Quality Council Chronic Disease Management Collaborative from 2005 to 2007. Dr. Padayachee served as President of the Saskatchewan Medical Association in 2006-2007 and as CEO of the Saskatchewan Medical Association from 2011 to February 2014.
Solace Therapeutics Adds New Member to Board of Directors
Business Wire - Tue Sep 17, 9:00AM CDT
Solace Therapeutics, a venture capital funded medical technology company focusing on treating stress urinary incontinence (SUI), announced today that Stacy Enxing Seng has joined the Board of Directors. She serves on the board alongside Ryan Drant, General Partner with New Enterprise Associates (NEA); Ali Behbahani MD, Principal at NEA; John McDonough, CEO at T2 Biosystems; and Kevin G. Connors, founding partner of Spray Venture Partners.